# RECQUIRED SAMPLE SIZES

<div style="text-align: justify">

This page is devoted to the calculation of the number of patients required for several studies such as an randomized clinical trial (RCT) for causal inference or a cohort for constructing or validating a predictive tool. R codes are proposed. We can click [here](https://poitiers-health-data.shinyapps.io/SampleSize/) to access to the related user-friendly calculators. Some reminders:

* **Superiority RCT:** Use to demonstrate that the experimental treatment is more effective than standard therapy.

* **Non-inferiority RCT:** Use to demonstrate that the experimental treatment is as effective as standard therapy.

* **Sequential RCT:** Intermediate analyses for early stopping the study.

## COMPARING TWO MEANS

### &nbsp;&nbsp;&nbsp;&nbsp;SUPERIORITY TRIALS

<details>
<summary>No intermediate anlysis</summary>
<br>

*Consider the following RCT with two parallel groups with a 1:1 randomization ratio. The expected mean is 66 units in patients in the experimental arm versus 72 units in the control arm. In order to demonstrate such a difference of 6 units, with a standard deviation of 23, a 5% two-sided type I error rate and a power of 80%, the minimum sample size per arm equals 231 (i.e., a total of 462 patients).*

```r
library(epiR)
		
epi.sscompc(treat = 66, control = 72,	sigma = 23, n = NA, power = 0.8, 
		      	r = 1, sided.test = 2, conf.level = 1-0.05)

#> $n.total
#> [1] 462

#> $n.treat
#> [1] 231

#> $n.control
#> [1] 231

#> $power
#> [1] 0.8

#> $delta
#> [1] 6
```

**Input parameters:**
* treat: expected mean in the experimental arm
* control: expected mean in the control arm
* sigma: expected standard deviation in the two arms
* power: recquired power (1 minus type II error rate)
* r: randomization ratio (experimental:control)
* sided.test: one-sided test (1) or two-sided test (2) 
* conf.level: recquired confidence level (1 minus type I error rate)

</summary>
</details>	

<details>
<summary>Sequential design</summary>
<br>

*Consider the following RCT with two parallel groups with a 1:1 randomization ratio and 2 planned intermediate analyses for efficacy by using the O'Brien-Fleming method for considering the inflation of the type I error rate). The expected mean is 66 units in patients in the experimental arm versus 72 units in the control arm. In order to demonstrate such a difference of 6 units, with a standard deviation of 23, a 5% two-sided type I error rate and a power of 80%,  the final analysis should be carried out on 472 patients (236 patients per group). The first and second intermediate analyses would be performed on 158 and 316 patients respectively, i.e. 33% and 66% of the maximum number of included patients if their is no decision of stopping the study.*

```r
library("rpact")
		
design <- getDesignGroupSequential(
               typeOfDesign = "OF", informationRates = c(1/3, 2/3, 1),
               alpha = 0.05, beta = 1-0.8, sided = 2)

designPlan <- getSampleSizeMeans(design, alternative = 6, stDev = 23,
                                 allocationRatioPlanned = 1)

summary(designPlan)

#> Stage                                          1       2       3 
#> Planned information rate                   33.3%   66.7%    100% 
#> Cumulative alpha spent                    0.0005  0.0143  0.0500 
#> Stage levels (two-sided)                  0.0005  0.0141  0.0451 
#> Efficacy boundary (z-value scale)          3.471   2.454   2.004 
#> Lower efficacy boundary (t)              -13.012  -6.405  -4.258 
#> Upper efficacy boundary (t)               13.012   6.405   4.258 
#> Cumulative power                          0.0329  0.4424  0.8000 
#> Number of subjects                         157.1   314.2   471.3 
#> Expected number of subjects under H1                       396.7 
#> Exit probability for efficacy (under H0)  0.0005  0.0138 
#> Exit probability for efficacy (under H1)  0.0329  0.4095 
```

**Input parameters:**
* typeOfDesign: type of design ("OF" for the O'Brien-Fleming method)
* informationRates: planned analyses defined as proportions of the maximum sample size
* alpha: recquired type I error rate
* beta: recquired type II error rate (1 minus power)
* sided: one-sided test (1), two-sided test (2)
* alternative: expected difference between the two arms
* stDev: expected standard deviation in the two arms
* allocationRatioPlanned: randomization ratio

</summary>	
</details>

### &nbsp;&nbsp;&nbsp;&nbsp;NON-INFERIORITY TRIALS

<details>
<summary>No intermediate anlysis</summary>
<br>

*Consider the following RCT with two parallel groups with a 1:1 randomization ratio. The expected mean is 66 units in patients in the control arm and no difference compared to the experimental arm. Assuming an absolute non-inferiority margin of 7 points, a standard deviation of 23, the minimum sample size per arm equals 134 (i.e., a total of 268 patients) to achieve a 5% one-sided type I error rate and a power of 80%*

```r
library(epiR)
	
epi.ssninfc(treat = 66, control = 66, sd= 23, delta = 7,
            power = 0.8, alpha = 0.05, r = 1, n = NA)

#> $n.total
#> [1] 268

#> $n.treat
#> [1] 134

#> $n.control
#> [1] 134

#> $delta
#> [1] 7

#> $power
#> [1] 0.8
```
	
**Input parameters:**
* treat: expected mean in the experimental arm
* control: expected mean in the control arm
* sd: expected standard deviation in the two arms
* delta: equivalence limit
* alpha: recquired type I error rate
* power: required power (1 minus type II error rate)
* r: randomization ratio (experimental:control)
* n: number of subjects to include (experimental + control) define as NA

</summary>
</details>

## COMPARING TWO PROPORTIONS

### &nbsp;&nbsp;&nbsp;&nbsp;SUPERIORITY

<details>
<summary>No intermediate anlysis</summary>
<br>

*Consider the following RCT with two parallel groups with a 1:1 randomization ratio. The expected proportion of events is 35% in the experimental arm compared to 28% in the control arm. In order to demonstrate such a difference of 7%, with a two-sided type I error rate of 5% and a power of 80%, the minimum sample size per arm equals 691 (i.e., a total of 1382 patients).*

```r
library(epiR)

epi.sscohortc(irexp1 = 0.35, irexp0 = 0.28, power = 0.80, r = 1,
              sided.test = 2, conf.level = 1-0.05)

#> $n.total
#> [1] 1382

#> $n.exp1
#> [1] 691

#> $n.exp0
#> [1] 691

#> $power
#> [1] 0.8

#> $irr
#> [1] 1.25

#> $or
#> [1] 1.384615
```
	
**Input parameters:**
*	irexp1: expected proportion in the experimental group
*	irexp0: expected proportion  in the control group
*	power: required power (1 minus type II error rate)
* r: randomization ratio (experimental:control)
* sided: one-sided test (1), two-sided test (2)
* conf.level: recquired confidence level (1 minus type I error rate)

</summary>
</details>

<details>
<summary>Sequential design</summary>
<br>

*Consider the following RCT with two parallel groups with a 1:1 randomization ratio and 2 planned intermediate analyses for efficacy by using the O'Brien-Fleming method for considering the inflation of the type I error rate. The expected proportion of event is 11% in patients in the experimental arm versus 15% units in the control arm. In order to demonstrate such a difference of 4%, with a 5% two-sided type I error rate and a power of 80%, the final analysis should be carried out on 2,256 patients (1,128 patients per group). The first and second intermediate analyses would be performed on 752 and 1,504 patients respectively, i.e. 33% and 66% of the maximum number of included patients if their is no decision of stopping the study.*

```r
library("rpact")
		
design <- getDesignGroupSequential(typeOfDesign = "OF", 
                informationRates = c(1/3, 2/3, 1), alpha = 0.05,
                beta = 1-0.8, sided = 2)

designPlan <- getSampleSizeRates(design,  pi1 = 0.11, pi2 = 0.15,
                   allocationRatioPlanned = 1)

summary(designPlan)

#> Stage                                         1      2      3 
#> Planned information rate                  33.3%  66.7%   100% 
#> Cumulative alpha spent                   0.0005 0.0143 0.0500 
#> Stage levels (two-sided)                 0.0005 0.0141 0.0451 
#> Efficacy boundary (z-value scale)         3.471  2.454  2.004 
#> Lower efficacy boundary (t)              -0.079 -0.042 -0.029 
#> Upper efficacy boundary (t)               0.101  0.048  0.031 
#> Cumulative power                         0.0329 0.4424 0.8000 
#> Number of subjects                        751.8 1503.7 2255.5 
#> Expected number of subjects under H1                   1898.1 
#> Exit probability for efficacy (under H0) 0.0005 0.0138 
#> Exit probability for efficacy (under H1) 0.0329 0.4095 
```

**Input parameters:**
* typeOfDesign: type of design ("OF" for the O'Brien-Fleming method)
* informationRates: planned analyses defined as proportions of the maximum sample size
* alpha: recquired type I error rate
* beta: recquired type II error rate (1 minus power)
* sided: one-sided test (1), two-sided test (2)
* pi1: expected probability in the experimental group
* pi2: expected probability in the control group
* allocationRatioPlanned: randomization ratio (experimental/control)

</summary>	
</details>

### &nbsp;&nbsp;&nbsp;&nbsp;NON-INFERIORITY

<details>
<summary>Normal design</summary>
<br>	

	
*Sample size for a randomised controlled non-inferiority trial in two parallel groups (experimental treatment A versus control treatment B) with balanced randomisation (ratio 1 :1) for a binary endpoint. 
The proportion of patients with an episode of hypertension was 35% with the B treatment. Assuming an absolute non-inferiority margin of 5%, with a one-sided alpha risk of 5% and a power of 80%, 
the sample size is related to the result of the script bellow :*
	
	
```r
epi.ssninfb(treat = 0.35, control = 0.35, delta = 0.05, 
			n = NA, r = 1, power = 0.8, alpha = 0.05)
```
	
**Parameters :**
* treat : proportion expected in the experimental group
* control : proportion expected in the control group
* delta : equivalence limit, which represents the clinically significant difference (>0)
* n : number of subjects to include (experimental + control), define as NA
* r : randomization ratio, number of patients of the experimental group divided by the number of patients of the control group
* power : power of the trial
* alpha : type I error rate

</details>

## BINARY EVENT PREDICTION

### &nbsp;&nbsp;&nbsp;&nbsp;CONSTRUCTION

Creation of a predictive tool that return the probability of a future event based on factors in order to inform clinical diagnosis and prognosis in healthcare.

<details>
<summary>Example</summary>
<br>	

*Sample size for developing a logistic regression model based on up to  candidate 34 predictors, with an anticipated R2 of at least 0.25, and to target an expected shrinkage of 0.9(equation 11 in Riley et al. Statistics in Medicine. 2019;38:1276â€“1296)."), the sample size is related to the result of the script bellow:*

```r
ceiling(34/((0.9-1)*log(1-0.25/0.9)))
```

**Parameters :**

* 34 : number of potential predictors
* 0.9  : expected shrinkage
* 0.25 : expected predictive capacities

</details>

### &nbsp;&nbsp;&nbsp;&nbsp;EXTERNAL VALIDATION

External validation for a predictive tool that return the probability of a future event based on factors in order to inform clinical diagnosis and prognosis in healthcare.

<details>
<summary>Example</summary>
<br>	

*Sample size for external validation of a logistic regression model based with an expected outcome event proportions of 50%, with a alpha risk at 5% and with a target confidence interval width of 20% (Riley et al.  Statistics in Medicine. 2021;19:4230-4251).*

```r
se <- function(width, alpha) # The standard error associated with the 1-alpha confidence interval
{
  fun <- function(x) { exp( qnorm(1-alpha/2, mean=0, sd=1) * x ) - exp(-1* qnorm(1-alpha/2, mean=0, sd=1) * x ) - width } 
  return(uniroot(fun, lower = 0.001, upper = 100)$root)
} 

size.calib <- function(p0, width, alpha) # the minimum sample size to achieve this precision
{   
  (1-p0) / ((p0 * se(width=width, alpha=alpha)**2 ))
}

size.calib(p0=0.5, width=0.2, alpha=0.05)
```

**Parameters :**

* p0 : expected event outcome proportion
* width  : size of the target confidence interval
* alpha : type I error rate

</details>